Need help finding what you are looking for?
Contact Us
PUBLISHER: Polaris Market Research | PRODUCT CODE: 1421656
PUBLISHER: Polaris Market Research | PRODUCT CODE: 1421656
Vaginitis Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Disease Type (Anti-fungal, Anti-bacterial, Hormone); By Product (OTC, Prescription); By Region, And Segment Forecasts, 2023 - 2032
PUBLISHED:
PAGES: 114 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
The global vaginitis therapeutics market size is expected to reach USD 7.20 billion by 2032, according to a new study by Polaris Market Research. The report "Vaginitis Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Disease Type (Anti-fungal, Anti-bacterial, Hormone); By Product (OTC, Prescription); By Region, And Segment Forecasts, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.
Several organizations, both governmental and non-governmental, have initiated programs aimed at creating awareness among women regarding vaginitis drugs, which has led to an increased demand for these drugs. Furthermore, the rising trend of alcohol consumption is expected to further boost the adoption of these drugs. Notably, in the United States, about 5.3 million women are at risk of health-related issues due to vaginitis.
In addition, the increasing focus on research and development of vaginitis therapeutics is expected to contribute to the growth of the market. Various studies funded by organizations such as the National Institute of Allergy and Infectious Diseases (NIAID) have yielded valuable insights into yeast generative behavior, which could lead to innovative treatment approaches for yeast infections. Moreover, the introduction of new medications by major pharmaceutical companies is projected to drive the market expansion, indicating a positive trend for the industry.
Probiotic therapy has gained significant research attention recently, in part due to the unsatisfactory outcomes of current treatments for Candida vaginitis. The most commonly used antifungal drugs for Candida vaginitis include Clotrimazole, Fluconazole, Miconazole, and Nystatin. However, some of these drugs only inhibit fungal growth without eradicating them entirely. Prolonged use can also harm normal vaginal cells and tissues, leading to imbalances in local vaginal microbiota, disruptions in acid-base balance, superinfections, and recurrent infections. Therefore, there is an urgent need to explore therapies for Candida vaginitis that can regulate the vaginal microenvironment.
Functional analysis has shown that when hyaluronic acid hydrogel is combined with nanozymes, it effectively eradicates Candida albicans even at lower hydrogen peroxide concentrations. Combining nanozymes with Lactobacillus led to a significant 70% reduction in fungal viability during Candida vaginitis treatment. In contrast, using Lactobacillus alone did not demonstrate any impact on fungal viability. In-depth analysis demonstrated that the joint application of nanozymes and Lactobacillus is remarkably efficient in producing hydroxyl radicals, causing substantial damage to the fungal cell membrane. Notably, this combination treatment did not adversely affect the Lactobacillus bacteria.
According to the Centers for Disease Control and Prevention (CDC), symptomatic BV patients should be treated with metronidazole, either orally twice a day for seven days, intravaginally daily for five days, or clindamycin gel intravaginally for seven days, as per their guidelines on sexually transmitted infections (STI) treatment. Research has shown that oral metronidazole provides temporary improvement in the vaginal microbiome for recurrent BV patients, but recurrence occurs by day 30 after therapy. Another study indicated that after initial treatment, the cure rate with Intravaginal Benznidazole (IBA) and nitroimidazole therapy was higher.
Vaginitis Therapeutics Market Report Highlights
- The anti-bacterial segment dominated the market owing to the availability of a wide product range and rising number of bacterial vaginosis cases
- The hormone segment will grow at a rapid pace due to the presence of a pipeline of products and adoption among medical practitioners
- North America dominated the market, primarily due to rising cases of vaginitis and awareness among patient
- The key market players include Pfizer, Merck, Novartis, Bayer, Lupin Pharmaceuticals, Symbiomix Therapeutics, and Mission Pharmacal.
Polaris Market Research has segmented the vaginitis therapeutics market report based on disease type, product, and region:
Viginitis Therapeutics, Disease Type Outlook (Revenue - USD Billion, 2019 - 2032)
- Anti-fungal
- Anti-bacterial
- Hormone
Viginitis Therapeutics, Product Outlook (Revenue - USD Billion, 2019 - 2032)
- Over-the-counter (OTC)
- Prescription
Viginitis Therapeutics, Regional Outlook (Revenue - USD Billion, 2019 - 2032)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Netherlands
- Asia Pacific
- China
- India
- Japan
- South Korea
- Indonesia
- Malaysia
- Latin America
- Argentina
- Brazil
- Mexico
- Middle East & Africa
- UAE
- Saudi Arabia
- Israel
- South Africa
Product Code: PM3987
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Vaginitis Therapeutics Market Insights
- 4.1. Vaginitis Therapeutics Market - Industry Snapshot
- 4.2. Vaginitis Therapeutics Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Increasing awareness and education on women's health
- 4.2.1.2. Technological advancements in diagnosis and treatment options
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Resistance to antibiotics and antifungal medications
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTLE Analysis
- 4.5. Vaginitis Therapeutics Industry trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
5. Global Vaginitis Therapeutics Market, by Disease Type
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Vaginitis Therapeutics, by Disease Type, 2019-2032 (USD Billion)
- 5.3. Anti-fungal
- 5.3.1. Global Vaginitis Therapeutics Market, by Anti-fungal, by Region, 2019-2032 (USD Billion)
- 5.4. Anti-bacterial
- 5.4.1. Global Vaginitis Therapeutics Market, by Anti-bacterial, by Region, 2019-2032 (USD Billion)
- 5.5. Hormone
- 5.5.1. Global Vaginitis Therapeutics Market, by Hormone, by Region, 2019-2032 (USD Billion)
6. Global Vaginitis Therapeutics Market, by Product
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 6.3. Over-the-counter (OTC)
- 6.3.1. Global Vaginitis Therapeutics Market, by Over-the-counter (OTC), by Region, 2019-2032 (USD Billion)
- 6.4. Prescription
- 6.4.1. Global Vaginitis Therapeutics Market, by Prescription, by Region, 2019-2032 (USD Billion)
7. Global Vaginitis Therapeutics Market, by Geography
- 7.1. Key findings
- 7.2. Introduction
- 7.2.1. Vaginitis Therapeutics Market Assessment, By Geography, 2019-2032 (USD Billion)
- 7.3. Vaginitis Therapeutics Market - North America
- 7.3.1. North America: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.3.2. North America: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- 7.3.3. Vaginitis Therapeutics Market - U.S.
- 7.3.3.1. U.S.: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.3.3.2. U.S.: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- 7.3.4. Vaginitis Therapeutics Market - Canada
- 7.3.4.1. Canada: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.3.4.2. Canada: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- 7.4. Vaginitis Therapeutics Market - Europe
- 7.4.1. Europe: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.4.2. Europe: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- 7.4.3. Vaginitis Therapeutics Market - UK
- 7.4.3.1. UK: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.4.3.2. UK: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- 7.4.4. Vaginitis Therapeutics Market - France
- 7.4.4.1. France: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.4.4.2. France: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- 7.4.5. Vaginitis Therapeutics Market - Germany
- 7.4.5.1. Germany: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.4.5.2. Germany: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- 7.4.6. Vaginitis Therapeutics Market - Italy
- 7.4.6.1. Italy: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.4.6.2. Italy: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- 7.4.7. Vaginitis Therapeutics Market - Spain
- 7.4.7.1. Spain: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.4.7.2. Spain: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- 7.4.8. Vaginitis Therapeutics Market - Netherlands
- 7.4.8.1. Netherlands: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.4.8.2. Netherlands: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- 7.4.9. Vaginitis Therapeutics Market - Russia
- 7.4.9.1. Russia: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.4.9.2. Russia: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- 7.5. Vaginitis Therapeutics Market - Asia Pacific
- 7.5.1. Asia Pacific: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.5.2. Asia Pacific: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- 7.5.3. Vaginitis Therapeutics Market - China
- 7.5.3.1. China: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.5.3.2. China: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- 7.5.4. Vaginitis Therapeutics Market - India
- 7.5.4.1. India: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.5.4.2. India: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- 7.5.5. Vaginitis Therapeutics Market - Malaysia
- 7.5.5.1. Malaysia: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.5.5.2. Malaysia: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- 7.5.6. Vaginitis Therapeutics Market - Japan
- 7.5.6.1. Japan: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.5.6.2. Japan: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- 7.5.7. Vaginitis Therapeutics Market - Indonesia
- 7.5.7.1. Indonesia: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.5.7.2. Indonesia: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- 7.5.8. Vaginitis Therapeutics Market - South Korea
- 7.5.8.1. South Korea: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.5.8.2. South Korea: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- 7.6. Vaginitis Therapeutics Market - Middle East & Africa
- 7.6.1. Middle East & Africa: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.6.2. Middle East & Africa: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- 7.6.3. Vaginitis Therapeutics Market - Saudi Arabia
- 7.6.3.1. Saudi Arabia: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.6.3.2. Saudi Arabia: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- 7.6.4. Vaginitis Therapeutics Market - UAE
- 7.6.4.1. UAE: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.6.4.2. UAE: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- 7.6.5. Vaginitis Therapeutics Market - Israel
- 7.6.5.1. Israel: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.6.5.2. Israel: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- 7.6.6. Vaginitis Therapeutics Market - South Africa
- 7.6.6.1. South Africa: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.6.6.2. South Africa: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- 7.7. Vaginitis Therapeutics Market - Latin America
- 7.7.1. Latin America: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.7.2. Latin America: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- 7.7.3. Vaginitis Therapeutics Market - Mexico
- 7.7.3.1. Mexico: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.7.3.2. Mexico: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- 7.7.4. Vaginitis Therapeutics Market - Brazil
- 7.7.4.1. Brazil: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.7.4.2. Brazil: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- 7.7.5. Vaginitis Therapeutics Market - Argentina
- 7.7.5.1. Argentina: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.7.5.2. Argentina: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
8. Competitive Landscape
- 8.1. Expansion and Acquisition Analysis
- 8.1.1. Expansion
- 8.1.2. Acquisitions
- 8.2. Partnerships/Collaborations/Agreements/Exhibitions
9. Company Profiles
- 9.1. Pfizer, Inc.
- 9.1.1. Company Overview
- 9.1.2. Financial Performance
- 9.1.3. Product Benchmarking
- 9.1.4. Recent Development
- 9.2. Merck & Co.
- 9.2.1. Company Overview
- 9.2.2. Financial Performance
- 9.2.3. Product Benchmarking
- 9.2.4. Recent Development
- 9.3. Novartis AG
- 9.3.1. Company Overview
- 9.3.2. Financial Performance
- 9.3.3. Product Benchmarking
- 9.3.4. Recent Development
- 9.4. Bayer AG
- 9.4.1. Company Overview
- 9.4.2. Financial Performance
- 9.4.3. Product Benchmarking
- 9.4.4. Recent Development
- 9.5. Lupin Pharmaceuticals, Inc.
- 9.5.1. Company Overview
- 9.5.2. Financial Performance
- 9.5.3. Product Benchmarking
- 9.5.4. Recent Development
- 9.6. Symbiomix Therapeutics, Inc.
- 9.6.1. Company Overview
- 9.6.2. Financial Performance
- 9.6.3. Product Benchmarking
- 9.6.4. Recent Development
- 9.7. Mission Pharmacal Company
- 9.7.1. Company Overview
- 9.7.2. Financial Performance
- 9.7.3. Product Benchmarking
- 9.7.4. Recent Development
Product Code: PM3987
List of Tables
- Table 1 Global Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- Table 2 Global Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- Table 3 Vaginitis Therapeutics Market Assessment, By Geography, 2019-2032 (USD Billion)
- Table 4 North America: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- Table 5 North America: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- Table 6 U.S.: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- Table 7 U.S.: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- Table 8 Canada: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- Table 9 Canada: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- Table 10 Europe: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- Table 11 Europe: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- Table 12 UK: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- Table 13 UK: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- Table 14 France: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- Table 15 France: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- Table 16 Germany: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- Table 17 Germany: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- Table 18 Italy: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- Table 19 Italy: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- Table 20 Spain: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- Table 21 Spain: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- Table 22 Netherlands: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- Table 23 Netherlands: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- Table 24 Russia: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- Table 25 Russia: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- Table 26 Asia Pacific: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- Table 27 Asia Pacific: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- Table 28 China: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- Table 29 China: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- Table 30 India: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- Table 31 India: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- Table 32 Malaysia: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- Table 33 Malaysia: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- Table 34 Japan: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- Table 35 Japan: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- Table 36 Indonesia: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- Table 37 Indonesia: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- Table 38 South Korea: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- Table 39 South Korea: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- Table 40 Middle East & Africa: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- Table 41 Middle East & Africa: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- Table 42 Saudi Arabia: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- Table 43 Saudi Arabia: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- Table 44 UAE: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- Table 45 UAE: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- Table 46 Israel: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- Table 47 Israel: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- Table 48 South Africa: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- Table 49 South Africa: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- Table 50 Latin America: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- Table 51 Latin America: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- Table 52 Mexico: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- Table 53 Mexico: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- Table 54 Brazil: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- Table 55 Brazil: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
- Table 56 Argentina: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
- Table 57 Argentina: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
List of Figures
- Figure 1 Global Vaginitis Therapeutics Market, 2019-2032 (USD Billion)
- Figure 2 Integrated Ecosystem
- Figure 3 Research Methodology: Top-Down & Bottom-Up Approach
- Figure 4 Market by Geography
- Figure 5 Porter's Five Forces
- Figure 6 Market by Product
- Figure 7 Global Vaginitis Therapeutics Market, by Product, 2022 & 2032 (USD Billion)
- Figure 8 Market by Disease Type
- Figure 9 Global Vaginitis Therapeutics Market, by Disease Type, 2022 & 2032 (USD Billion)
- Figure 10 Vaginitis Therapeutics Market Assessment, By Geography, 2019-2032 (USD Billion)
- Figure 11 Strategic Analysis - Vaginitis Therapeutics Market
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.